World PulseNow
Newsletter

U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims

Investing.com•Tuesday, September 16, 2025 at 9:43:49 PM
NegativeFinancial Markets
U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims
The U.S. FDA has issued warning letters to major pharmaceutical companies Lilly, Novo, and Hims regarding their drug advertising practices. This action highlights concerns over misleading information that could affect patient safety and treatment decisions. The FDA's intervention is crucial as it aims to ensure that consumers receive accurate information about medications, ultimately protecting public health.
— Curated by the World Pulse Now AI Editorial System
Read Original

Was this article worth reading? Share it

Recommended Readings
Lilly weight-loss pill could be FDA-approved by year-end
Investing.com29 minutes ago
Lilly weight-loss pill could be FDA-approved by year-end
PositiveFinancial Markets
Lilly's weight-loss pill is on track for potential FDA approval by the end of the year, which could be a game-changer for those struggling with obesity. This development is significant as it may provide a new, effective treatment option for millions, addressing a growing health crisis and offering hope for better weight management.
Read full article
via Investing.com
FDA warns Hims & Hers and other weight loss drugmakers to remove ‘false and misleading’ advertising
Fortune2 hours ago
FDA warns Hims & Hers and other weight loss drugmakers to remove ‘false and misleading’ advertising
NegativeFinancial Markets
The FDA has issued over 100 letters to Hims & Hers and other weight loss drugmakers, warning them to stop using false and misleading advertising. This action highlights concerns about the integrity of marketing practices in the weight loss industry.
Editor’s Note: This matters because misleading advertising can lead consumers to make uninformed health decisions. The FDA's intervention aims to protect public health and ensure that companies provide accurate information about their products.
Read full article
via Fortune
FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs
Forbes4 hours ago
FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs
NegativeFinancial Markets
The FDA has issued warnings to Hims and over 100 other companies for making false claims about compounded weight-loss drugs. This action highlights concerns over misleading advertising in the pharmaceutical industry.
Editor’s Note: This matters because misleading advertisements can lead consumers to make uninformed health decisions. The FDA's intervention aims to protect public health and ensure that companies provide accurate information about their products.
Read full article
via Forbes
Hims & Hers stock falls after FDA warning over semaglutide claims
Investing.com7 hours ago
Hims & Hers stock falls after FDA warning over semaglutide claims
NegativeFinancial Markets
Hims & Hers stock has dropped following a warning from the FDA regarding their claims about semaglutide. This has raised concerns among investors about the company's future.
Editor’s Note: The FDA's warning can significantly impact a company's reputation and stock performance. Investors are closely monitoring how Hims & Hers will respond to this challenge and what it means for their product offerings.
Read full article
via Investing.com
Brainsway stock surges after FDA clears accelerated depression treatment
Investing.com8 hours ago
Brainsway stock surges after FDA clears accelerated depression treatment
PositiveFinancial Markets
Brainsway's stock price has surged following the FDA's approval of its accelerated treatment for depression. This breakthrough could provide new hope for patients struggling with this condition.
Editor’s Note: The FDA's clearance of Brainsway's treatment is significant as it may offer faster relief for those suffering from depression. This approval not only boosts the company's stock but also highlights advancements in mental health therapies.
Read full article
via Investing.com
Krystal Biotech stock receives Buy rating as FDA expands VYJUVEK label
Investing.com10 hours ago
Krystal Biotech stock receives Buy rating as FDA expands VYJUVEK label
PositiveFinancial Markets
Krystal Biotech's stock has received a Buy rating following the FDA's expansion of the VYJUVEK label, indicating strong market confidence in the company's growth potential.
Editor’s Note: This development is significant as it reflects the FDA's recognition of VYJUVEK's effectiveness, which could lead to increased sales and investor interest, boosting Krystal Biotech's market position.
Read full article
via Investing.com
Akeso’s cancer therapy gets orphan status from US FDA
Investing.com17 hours ago
Akeso’s cancer therapy gets orphan status from US FDA
PositiveFinancial Markets
Akeso's cancer therapy has received orphan drug designation from the US FDA, which can accelerate its development and approval process.
Editor’s Note: This designation is significant as it provides incentives for companies to develop treatments for rare diseases, potentially leading to faster access for patients in need.
Read full article
via Investing.com
Krystal Biotech stock jumps after FDA expands VYJUVEK label
Investing.coma day ago
Krystal Biotech stock jumps after FDA expands VYJUVEK label
PositiveFinancial Markets
Krystal Biotech's stock surged following the FDA's decision to expand the label for its product VYJUVEK. This expansion is expected to enhance the product's market potential and boost investor confidence.
Editor’s Note: The FDA's approval is a significant milestone for Krystal Biotech, as it not only validates the efficacy of VYJUVEK but also opens new avenues for treatment options. This could lead to increased sales and a stronger position in the biotech market.
Read full article
via Investing.com
Latest from Financial Markets
Ouster CEO Pacala sells $1.08 million in shares
Investing.com19 minutes ago
Ouster CEO Pacala sells $1.08 million in shares
NeutralFinancial Markets
Ouster CEO Angus Pacala has sold $1.08 million worth of shares, a move that raises questions about the company's future direction and his confidence in its performance. This sale comes at a time when Ouster is navigating a competitive landscape in the lidar technology sector, making it a noteworthy event for investors and industry watchers.
Read full article
via Investing.com
Community West Bancshares EVP Cagle buys $3556 in stock
Investing.com19 minutes ago
Community West Bancshares EVP Cagle buys $3556 in stock
PositiveFinancial Markets
In a notable move, Cagle, the Executive Vice President of Community West Bancshares, has purchased $3,556 worth of stock in the company. This investment reflects confidence in the bank's future and could signal positive growth ahead. Such insider buying often reassures investors and can lead to increased interest in the stock.
Read full article
via Investing.com
Rambus SVP, CFO Lynch sells $832k in stock
Investing.com19 minutes ago
Rambus SVP, CFO Lynch sells $832k in stock
NeutralFinancial Markets
Rambus Senior Vice President and Chief Financial Officer, Lynch, has sold $832,000 worth of stock. This transaction is significant as it reflects Lynch's financial decisions and could indicate confidence or strategy regarding the company's future. Such stock sales by executives often attract attention from investors and analysts, as they can be seen as a signal of the company's performance or outlook.
Read full article
via Investing.com
Boeing secures $82 million in defense contracts for space and aviation
Investing.com22 minutes ago
Boeing secures $82 million in defense contracts for space and aviation
PositiveFinancial Markets
Boeing has successfully secured $82 million in defense contracts, focusing on advancements in space and aviation. This is significant as it not only strengthens Boeing's position in the defense sector but also highlights the growing importance of aerospace technology in national security. The contracts are expected to enhance capabilities and innovation, benefiting both the company and the military.
Read full article
via Investing.com
Ouster’s Chung sells $488,995 in shares
Investing.com25 minutes ago
Ouster’s Chung sells $488,995 in shares
NeutralFinancial Markets
Ouster's CEO, Angus Chung, has sold nearly $489,000 worth of shares in the company. This move is significant as it reflects the ongoing financial strategies within the tech sector, particularly in the lidar industry. Investors often scrutinize such transactions to gauge the confidence of company leaders in their own business's future.
Read full article
via Investing.com
Datadog director Shah Shardul sells $1.09 million in shares
Investing.com25 minutes ago
Datadog director Shah Shardul sells $1.09 million in shares
NeutralFinancial Markets
Shah Shardul, a director at Datadog, has sold $1.09 million worth of shares in the company. This move is significant as it reflects the ongoing trends in stock trading among executives, which can influence investor sentiment and market dynamics. While such sales can raise questions about insider confidence, they are also common practices in corporate governance.
Read full article
via Investing.com